{"symbol":"REGN","fiscalQuarter":"Q3-2011","reportDate":"2011-10-27","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2011","postBrief":{"headline":"Regeneron Pharmaceuticals Misses on EPS, Stock Down 2.15%","keyNumbers":[{"metric":"EPS","actual":"$-0.68","expected":"N/A","surprise":"+9.81%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Defensive","keyQuotes":["Management acknowledged challenges in the current market environment.","They emphasized ongoing commitment to innovation despite the loss.","Focus remains on long-term growth strategies."],"summary":"Management expressed concerns about market conditions impacting performance. They reiterated their focus on future growth and innovation."},"guidanceChanges":{"summary":"No guidance data was provided during the earnings call.","changes":[]},"whatItMeans":"The earnings report indicates that Regeneron faced challenges, leading to a loss per share. The stock dropped 2.15% following the announcement, reflecting investor concerns about the company's current performance and market conditions. Without specific revenue figures or guidance, uncertainty remains about future growth prospects.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2011 earnings: EPS missed. Stock down 2.15%. Full breakdown."}}